http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
재발성 카포시수두양발진의 임상적 특징과 유발요인에 대한 분석
배경남 ( Kyung-nam Bae ),김태욱 ( Taewook Kim ),박성민 ( Sungmin Park ),이현주 ( Hyun Joo Lee ),진현주 ( Hyunju Jin ),유향석 ( Hyangsuk You ),심우행 ( Woo-haing Shim ),김건욱 ( Gun-wook Kim ),김훈수 ( Hoon-soo Kim ),고현창 ( Hyun- 대한피부과학회 2019 대한피부과학회지 Vol.57 No.9
Background: Kaposi varicelliform eruption (KVE) is a disseminated viral infection primarily caused by the herpes simplex virus in the setting of an underlying chronic skin disease. Few studies have reported the clinical characteristics and predisposing factors for recurrent KVE. Objectives: To characterize the clinical features and predisposing factors for recurrent KVE. Methods: This retrospective comparative study of recurrent vs. single-episode KVE was performed at the Pusan National University Hospital between 2004 and 2017. Results: A total of 84 episodes occurred in 60 patients, and of these, 13 patients developed recurrence (21.7%). No statistically significant intergroup difference was observed in the mean age and sex distribution. The face was the most common site of involvement in both groups, followed by the trunk and the upper and lower extremities. Atopic dermatitis was the most common pre-existing disease in both groups; however, Darier’s disease was more common in the recurrent KVE group, and this difference was statistically significant. Most patients with KVE (66.7%) showed aggravation of the underlying skin disease within 3 months of KVE onset. This finding was more prominent in patients with recurrent episodes (91.7%) than in those with single-episode KVE (58.3%), (p=0.040). Conclusion: This study can contribute to a better understanding of recurrent KVE and guide clinicians in treating patients with conditions predisposing to KVE. (Korean J Dermatol 2019;57(9):519∼526)
중등도-중증의 한국인 건선 환자에서 Ustekinumab 장기 투여에 따른 효과 및 안전성 연구
김연아 ( Yeona Kim ),배경남 ( Kyung-nam Bae ),손진화 ( Jin-hwa Son ),신기혁 ( Kihyuk Shin ),김훈수 ( Hoonsoo Kim ),고현창 ( Hyun-chang Ko ),김문범 ( Moon-bum Kim ),신봉석 ( Bong Seok Shin ),김병수 ( Byungsoo Kim ) 대한피부과학회 2022 대한피부과학회지 Vol.60 No.3
Background: Ustekinumab is a humanized monoclonal antibody targeting interleukin (IL)-12 and IL-23. Although popular, data on its long-term efficacy and safety in Korean patients with psoriasis are limited. Objective: To evaluate the long-term efficacy and safety of ustekinumab in Korean patients with psoriasis. Methods: A retrospective study in patients with moderate-to-severe psoriasis who had been treated with ustekinumab for at least 5 years was conducted. The sex, age, body mass index, medical records, previous psoriasis therapy, psoriasis area and severity index (PASI) scores, and adverse events were evaluated. Results: Twenty-five patients (median age 47.00 years) had been treated with ustekinumab for 5 years. The mean duration of psoriasis was 19.12±8.45 years, and the treatment duration with ustekinumab was 285.12±8.48 weeks. The baseline PASI was 17.52±7.38. PASI75 was achieved in 84% of the patients at week 28, and 96% of the patients maintained PASI75 during the 5-year follow-up period. Furthermore, 56% of patients reached PASI90 at 28 weeks, and 48% of patients maintained PASI90 for 5 years. No unexpected adverse events other than herpes zoster, herpes simplex, or elevated liver enzymes were reported. Conclusion: Ustekinumab demonstrated long-lasting efficacy with an acceptable safety profile in Korean patients with moderate-to-severe psoriasis. (Korean J Dermatol 2022;60(3):151∼158)
소아 피부근염의 임상적 특징과 예후: 후향적 연구 및 문헌 고찰
김태림 ( Tae-rim Kim ),배경남 ( Kyung-nam Bae ),손진화 ( Jin-hwa Son ),신기혁 ( Kihyuk Shin ),김훈수 ( Hoon-soo Kim ),고현창 ( Hyun-chang Ko ),김문범 ( Moon-bum Kim ),김병수 ( Byung-soo Kim ) 대한피부과학회 2021 대한피부과학회지 Vol.59 No.9
Background: Juvenile dermatomyositis (JDM) is a rare but common childhood idiopathic inflammatory myopathy. Proximal muscle weakness and pathognomonic skin rash, Gottron papules, and heliotrope rash are characteristic clinical features of JDM. However, clinical analysis of JDM has rarely been reported in the Korean dermatologic literature. Objective: This study aimed to investigate the clinical features and outcomes of JDM in Korea and previous studies. Methods: We retrospectively reviewed the medical records and clinical photographs of patients diagnosed with JDM at Pusan National University Hospital (Busan and Yangsan) for 17 years (2005∼2021). Results: We encountered 12 patients with JDM (male to female ratio=7:5) with a mean age of 7.2 years. The most common clinical features were Gottron papules (100%), followed by Gottron sign (83.3%), malar rash (58.3%), heliotrope rash (41.7%), shawl sign (16.7%), calcinosis cutis (8.3%), and ulcer (8.3%). In all cases, there was no concurrent interstitial lung disease or an underlying malignancy. Only 1 of 12 patients complained of proximal muscle weakness, and four patients showed an increase in muscle enzymes in the laboratory test. The skin lesions gradually improved after systemic steroid or topical treatment in all cases. No additional proximal muscle weakness was found during the follow-up. Conclusion: Although proximal muscle weakness is a common symptom in JDM, clinically amyopathic JDM is commonly found in dermatologic clinics. Regardless of subtype, all patients responded well to treatment and rarely encountered recurrence. (Korean J Dermatol 2021;59(9):699∼706)
Brentuximab Vedotin로 치료한 CD30 양성 대세포 이행을 보인 균상식육종 1예
신준오 ( Jun-oh Shin ),배경남 ( Kyung-nam Bae ),손진화 ( Jin-hwa Son ),신기혁 ( Kihyuk Shin ),김훈수 ( Hoon-soo Kim ),고현창 ( Hyun-chang Ko ),김문범 ( Moon-bum Kim ),김병수 ( Byungsoo Kim ) 대한피부과학회 2022 대한피부과학회지 Vol.60 No.2
Large-cell transformation of mycosis fungoides (LCT-MF) is an advanced stage of primary cutaneous T-cell lymphoma with a poor prognosis. Therapeutic options for these patients are often limited, and so far, they are not promising. An 81-year-old woman with a previous history of mycosis fungoides presented with aggravation of generalized erythematous scaly patches and new onset of ulcerated tumor on the abdomen for 3 months. Histopathological examination revealed a dense dermal infiltrate composed of atypical large lymphocytes. Immunohistochemically, the tumor cells were positive for CD30 expression. A diagnosis of CD30<sup>+</sup> LCT-MF was established. She was intensively treated with methotrexate (1 month), acitretin (1 month), and rituximab with dose-modified cyclophosphamide, doxorubicin, and prednisone (1 cycle). Despite such treatments, the improvement was minimal. Subsequently, the patient was started on brentuximab vedotin, 1.8 mg/kg intravenously once every 3 weeks. She responded well to brentuximab therapy, and the skin lesions completely subsided within 12 weeks of treatment. (Korean J Dermatol 2022;60(2):106∼110)
이기욱 ( Gi-wook Lee ),김연아 ( Yeona Kim ),원상현 ( Sang-hyeon Won ),배경남 ( Kyung-nam Bae ),이정수 ( Jungsoo Lee ),신기혁 ( Kihyuk Shin ),김훈수 ( Hoon-soo Kim ),김병수 ( Byung-soo Kim ),김문범 ( Moon-bum Kim ),고현창 ( Hyun-ch 대한피부과학회 2023 대한피부과학회지 Vol.61 No.4
The phenotypic variability of variant Turner syndrome is wide, ranging from characteristic clinical features to those that are hardly distinguishable from the general population. A 4-year-old girl presented with multiple brownish macules and patches on the trunk and upper extremities as well as axillary freckles. Exome sequencing and chromosomal microarray testing revealed a microdeletion at Xp22.33p22.11 leading to a diagnosis of Turner syndrome. Here we describe an unusual case of variant Turner syndrome with multiple café-au-lait spots. (Korean J Dermatol 2023;61(4):244∼247)
Efavirenz, indinavir, lopinavir, ritonavir의 LC-MS/MS를 이용한 동시 정량법
채정우,배경진,백인환,서정원,이병요,이은주,남진경,강원구,권광일 충남대학교 약학대학 의약품개발연구소 2009 藥學論文集 Vol.24 No.-
Efavirenz indinavir and kaleta (co-formulation of lopinavir and ritonavir) are important antiretroviral drugs which have been proved to be human immunodeficiency virus (HIV) protease inhibitors and reduced the morbidity and mortality associated with HIV-1 infection. A brief and fast high performance liquid chromatography coupled with electrospray mass spectrometry (LC-MS/MS, API 4000) method for the determination of 4 anti-retroviral agents (efavirenz, lopinavir, indinavir, ritonavir) in human plasma was developed and validated. A simple protein precipitation method was used on 100μl of human plasma. And internal standard solution (10 ng/ml methaqualone) 1ml and reconstitution solution (MeOH) 1ml were added. After vortexing for 30 s and centrifuging at 13,200rpm for 10min, 2μl of supernatant was injected into the column (XTerra MS C_(18) column, 2.1mm × 50mm 3.5㎛ particle size). The mobile phase consisted of MeOH and 0.1% formic acid in water (80:20 , v/v). The chromatogram was run for 1.5 min at a flow rate of 300μl/min. A triple quadrupole mass spectrometer was operated in a positive ion mode (lopinavir, indinavir, ritonavir) and negative mode (efavirenz), simultaneously and multiple reaction monitoring (MRM) was used for drug quantification. The precursor-to-product ion transitions of m/z 316→69 (efavirenz) and 629→447 (lopinavir) and 614→421 (indinavir) and 721→296 (ritonavir)were used to measure and quantify the analyte. The limit of quantitation (LOQ) was 50 ng/ml (efavirenz, indinavir, ritonavir) and 100 ng/ml (lopinavir). The weighted (l/y²) calibration curve was linear over human plasma range 50∼5000ng/ml (efavirenz), 100∼20000ng/ml (lopinavir), 50∼10000ng/ml (indinavir), 50∼2000ng/ml (ritonavir), correlation coefficient(r²) of 4 antiretroviral agents were higher than 0.998. Accuracies and intra-run precisions ranged within 86.60 and 113.29%, 1.06 and 11.16% for all 4 drugs analysed. This analytical method used to determine these drugs was fast and easy to perform, with minimal sample preparation, and without compromising precision and accuracy. The developed method was successful to determine antiretroviral agents in human plasma, and proved suitable for clinical pharmacokinetic study.